Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver

Yong-hua ZHAN; Xue-hong WANG; Fang WANG

doi:10.13422/j.cnki.syfjx.20200833

您当前的位置：

首页 >

文章列表页 >

Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver

Clinic | 更新时间：2021-02-09

- Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 27, Issue 3, Pages: 117-122(2021)
- 作者机构：
  
  青海大学附属医院，西宁 810001
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20200833
  CLC： R289;R25;R259
- Received：16 April 2020，
  
  Published Online：28 May 2020，
  
  Published：05 February 2021
- 稿件说明：
移动端阅览
绽永华,王学红,王芳.半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察[J].中国实验方剂学杂志,2021,27(03):117-122.

ZHAN Yong-hua,WANG Xue-hong,WANG Fang.Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(03):117-122.
绽永华,王学红,王芳.半夏泻心汤加减对非酒精性脂肪肝的临床疗效及对胰岛素抵抗的调节效果观察[J].中国实验方剂学杂志,2021,27(03):117-122. DOI： 10.13422/j.cnki.syfjx.20200833.

ZHAN Yong-hua,WANG Xue-hong,WANG Fang.Regulatory Effect of Modified Banxia Xiexintang on Insulin Resistance of Patients with Nonalcoholic Fatty Liver[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(03):117-122. DOI： 10.13422/j.cnki.syfjx.20200833.

摘要

目的

观察半夏泻心汤加减治疗非酒精性脂肪肝（NAFLD）的临床疗效及对胰岛素抵抗（IR）调节效果。

方法

将140例患者按1∶1随机按数字表法分为对照组和观察组。对照组脱落/失访4例，违背方案剔除3例，完成63例；观察组脱落/失访5例，完成65例。两组均给予生活方式干预、保肝和调脂等处理。对照组口服化滞柔肝颗粒，1袋/次，3次/d；观察组内服半夏泻心汤加减，1剂/d；两组疗程均为治疗12周，并随访12周。采用瞬时弹性记录仪测量肝脏脂肪含量，测量空腹血糖（FGP）和空腹胰岛素（FINS），并计算胰岛素敏感指数（ISI），胰岛素抵抗指数（HOMA-IR）和胰岛

细胞功能指数（HOMA-

），治疗前、治疗后和随访时各评价1次；进行治疗前后腹部B超检查；测量肝/脾CT；检测治疗前后丙氨酸氨基转移酶（ALT），天冬氨酸氨基转移酶（AST），总胆固醇（TC），甘油三酯（TG），高密度脂蛋白胆固醇（HDL-C），低密度脂蛋白胆固醇（LDL-C），脂联素、瘦素、丝氨酸蛋白酶抑制剂（Vaspin），肿瘤坏死因子（TNF-

）和白细胞介素-6（IL-6）水平；进行治疗前后中医证候评分；进行安全性评价。

结果

观察组患者治疗后和随访期CAP和HOMA-IR均低于对照组（

0.01），ISI和HOMA-

均高于对照组（

0.01）；观察组患者血脂各指标的改善均高于对照组（

0.01）；观察组ALT，AST，FBG和FINS均低于对照组（

0.01）；观察组中医证候评分低于对照组（

0.01），肝/脾CT高于对照组（

0.01）；观察组TNF-

，IL-6，Vaspin和瘦素水平均低于对照组（

0.01），脂联素水平高于对照组（

0.01）；观察组腹部B超疗效和肝脏脂肪含量测定疗效均高于对照组（

0.05）。两组试验期间均无严重不良事件，没有发现与药物相关不良反应。

结论

半夏泻心汤加减治疗NAFLD肝胃不和、湿浊内停型患者，可调节糖、脂代谢，提高了胰岛素敏感性和HOMA-

细胞功能，改善了IR，并能调节脂肪细胞因子、炎症因子，减轻了临床症状和肝脏脂肪含量，提高了肝/脾CT，有着较好的临床疗效和安全性。

Abstract

Objective

To observe the clinical efficacy of modified Banxia Xiexintang on nonalcoholic fatty liver （NAFLD） and the regulatory effect on insulin resistance （IR）.

Method

One hundred and forty patients were randomly divided into control group and observation group. A total of 63 patients in control group completed the therapy （4 patients fell off or were lost to follow-up， 3 were eliminated）， while 65 patients in observation group completed the therapy （5 patients fell off or were lost to follow-up， none was eliminated）. Both groups' patients got lifestyle intervention， liver protection and lipid regulation. Patients in control group got Huazhi Rougan granule， 1 pack/time， 3 times/day. Patients in observation group got modified Banxia Xiexintang， 1 dose/day. And the course of treatment for the two groups was 12 weeks， and a 12 week follow-up was recorded. Before and after treatment and during the follow-up， fat content of liver was recorded by instantaneous elastic recorder， fasting blood glucose （FBG） and fasting insulin （FINS） were detected， and insulin sensitivity index （ISI）， insulin resistance index （HOMA-IR） and islet

cell function index （HOMA-

） were detected. After treatment， B-mode ultrasonography and ratio of liver/spleen CT were detected. And levels of alanine transaminase （ALT）， aspartate transaminase （AST）， total cholesterol （TC）， triglyceride （TG）， high-density lipoprotein cholesterol （HDL-C）， low-density lipoprotein cholesterol （LDL-C）， adiponectin， leptin， serine protease inhibitor （Vaspin）， tumor necrosis factor （TNF）-

and interleukin-6 （IL-6） were detected. And the safety was evaluated.

Result

CAP and HOMA-IR in observation group were lower than those in control group after treatment and during the follow-up （

0.01）， and ISI and HOMA-

were higher than those in control group （

0.01）. Amelioration of indexes of blood lipid was better than those in control group （

0.01）. Levels of ALT， AST， FBG and FINS were lower than those in control group （

0.01）. Scores of traditional Chinese medicine （TCM） syndromes were lower than those in control group （

0.01）， ratio of liver/spleen CT and adiponectin was higher than that in control group （

0.01）. Levels of TNF-

， IL-6， vaspin and leptin were lower than those in control group （

0.01）. B-ultrasound efficacy and fat content of liver were superior to those of control group （

0.05）. There were no serious adverse events and drug-related adverse reactions.

Conclusion

Modified Banxia Xiexintang can regulate glucose and lipid metabolism， improve insulin sensitivity and HOMA-

cell function， improve IR， regulate adipocytokines and inflammatory factors， relieve clinical symptoms and liver fat content， and improve CT ratio of liver/spleen， with a better clinical efficacy and safety.

关键词

Keywords

references

中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会 . 非酒精性脂肪性肝病防治指南（2018更新版）［J］. 中华肝脏病杂志， 2018 ， 26 （ 3 ）： 195 - 203 .

YOUNOSSI Z M ， KOENIG A B ， ABDELATIF D ， et al . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence， incidence， and outcomes ［J］. Hepatology ， 2016 ， 64 （ 1 ）： 73 - 84 .

中华医学会内分泌学分会 . 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识（第二版）［J］. 中华内分泌代谢杂志， 2018 ， 34 （ 7 ）： 549 - 554 .

中华中医药学会脾胃病分会 . 非酒精性脂肪性肝病中医诊疗专家共识意见（2017）［J］. 中医杂志， 2017 ， 58 （ 19 ）： 1706 - 1710 .

陈成，慕永平，冯琴 . 非酒精性脂肪性肝炎的中医病机特点探讨［J］. 世界科学技术—中医药现代化， 2016 ， 18 （ 9 ）： 1483 - 1487 .

彭林佳，刁建新，王琳琳 . 半夏泻心汤药理作用研究进展［J］. 中国医药导报， 2019 ， 16 （ 36 ）： 37 - 39，45 .

史丽伟，杜立娟，倪青 . 半夏泻心汤治疗糖尿病的理论探讨与临床应用［J］. 中医杂志， 2018 ， 59 （ 3 ）： 246 - 250 .

陈怡，刘文华 . “ 半夏泻心汤-积证、大柴胡汤-肝浊”经方辨治脂肪肝［J］. 实用中医内科杂志， 2017 ， 31 （ 1 ）： 61 - 62 .

LEDINGHEN V D ， WONG L H ， VERGNIOL J ， et al . Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease ［J］. J Gastroenterol Hepatol ， 2016 ， 31 （ 4 ）： 848 - 855 .

姚诚子，冯巩，宇文思，等 . 非酒精性脂肪性肝病发生及进展的危险因素［J］. 临床肝胆病杂志， 2020 ， 36 （ 2 ）： 433 - 436 .

王虎，滕田，王莉，等 . 非酒精性脂肪性肝病发病机制的研究进展［J］. 临床肝胆病杂志， 2017 ， 33 （ 4 ）： 769 - 773 .

KANWAR P ， KOWDLEY K V . The metabolic syndrome and its iinfluenceon nonalcoholic steatohepatitis ［J］. Clin Liver Dis ， 2016 ， 20 （ 2 ）： 225 - 243 .

王虎，滕田，王莉，等 . 非酒精性脂肪性肝病发病机制的研究进展［J］. 临床肝胆病杂志， 2017 ， 33 （ 4 ）： 769 - 773 .

姜雯，梁晓春 . 中医药防治代谢综合征胰岛素抵抗的研究进展［J］. 世界中西医结合杂志， 2019 ， 14 （ 7 ）： 1028 - 1032 .

POLYZOS S A ， KLUNTOURAS J ， MANTZOROS C S . Leptin in nonalcoholic fatty liver disease： a narrative review ［J］. Metabolism ， 2015 ， 64 （ 1 ）： 60 - 78 .

INZAUGARAT M E ， D E MATTEO E ， BAZ P ， et al . New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans ［J］. PLoS One ， 2017 ， 12 （ 3 ）： e0172900 .

YAMAUCHI T ， IWABU M ， OKADA-IWABU M ， et al . Adiponectin receptors： a review of their structure， function and how they work ［J］. Best Pract Res Clin Endocrinol Metab ， 2014 ， 28 （ 1 ）： 15 - 23 .

SAXENA N K ， ANANIA F A . Adipocytokines and hepatic fibrosis ［J］. Trends Endocrinol Metab ， 2015 ， 26 （ 3 ）： 153 - 61 .

王俊俊，陆伦根，蔡晓波 . 脂肪因子在非酒精性脂肪性肝病中的作用［J］. 国际消化病杂志， 2019 ， 39 （ 3 ）： 149 - 152，215 .

李建鸿，黄清华，莫小艾，等 . 桃核承气汤加减结肠水疗对痰热瘀结型重度非酒精性脂肪肝炎症因子及胰岛素抵抗的影响［J］. 中国实验方剂学杂志， 2020 ， 26 （ 3 ）： 37 - 42 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Total Saponins of Dioscorea Mitigate Nonalcoholic Steatohepatitis in Mice by Regulating AMPK/SREBP-1c/ACC Signaling Pathway

Meridian Tropism of Components in Bupleuri Radix Based on Nonalcoholic Steatohepatitis Model and Principal Component Analysis

Effect of Qinggan Tiaozhi Decoction on Lipid Peroxidatic in Rat Nonalcoholic Steatohepatitis

Related Author

CHEN Guangliang

LI Guoying

WANG Xin

WANG Dandan

LIU Yuyan

Jiexin CHEN

Haixue KUANG

Yonggang XIA

Related Institution

College of Integrated Chinese and Western Medicine， Anhui University of Chinese Medicine

Anhui Province Key Laboratory of Chinese Medicinal Formula

Key Laboratory of Basic and Application Research of Beiyao，Ministry of Education， Key Laboratory of Traditional Chinese Medicine （TCM） Pharmacodynamic Material Base， Heilongjiang University of Chinese Medicine

School of TCM， Guangdong Pharmaceutical University

Department of infectious disease,Beijing University First Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰